Home / Investors / Equity Story

Equity Story

For over 50 years we have developed and marketed high quality tests capable of providing a speedy response to the needs of labs throughout the world.

What we do

We are a robust and reliable company operating in the field of biotechnologies, within which we develop, produce and market tests for diagnosing changes to the patient’s health, following infection, hormonal changes or cancer.

We are committed to improving the quality of life of people via preventive identification of potential clinical diseases using a broad range of products of the highest quality.

Technologies

IMMUNODIAGNOSTICS
MOLECULAR DIAGNOSTICS

OUR OFFER

Our offer includes both high routine and specialty tests in a wide range of clinical areas.

44 ME TOO TESTS

Main characteristics

  • No R&D investments
  • Low menu differentiation
  • Very low marketing and R&D costs

42 HIGH VOLUME SPECIALTIES

Main characteristics

  • Low R&D investments
  • Menu differentiation
  • Low marketing and R&D costs

32 DIFFERENTIATING SPECIALTIES

Main characteristics

  • Significant R&D investments
  • High menu differentiation
  • Significant marketing and R&D costs

OUR TECHNOLOGICAL PLATFORMS

OUR CUSTOMERS

We serve all laboratories, offering fully automated solutions.

  • Big sized labs
  • Medium sized labs and hospital labs
  • Small sized labs and POLs (Physician Office Labs)

OUR OFFER

Our offer includes diagnostic tests and Analyte Specific Reagents.

OUR TECHNOLOGICAL PLATFORMS

The LIAISON® MDX is an innovative thermocycler based on PCR technology (Polymerase Chain Reaction) with two disc options: the 8-well Direct Amplification Disc and the 96-well Universal Disc.

OUR CUSTOMERS

We serve all laboratories, offering fully automated solutions.

  • Big sized labs
  • Medium sized labs and hospital labs
  • Small sized labs and POLs (Physician Office Labs)

Where we are

DiaSorin’s global presence is steadily growing.

To date, the Group headed by DiaSorin S.p.A. consists of 24 companies and 5 foreign branches, with offices across 5 continents and manufacturing premises producing its tests in 7 sites around the world.

DiaSorin markets its own tests and platforms worldwide through its commercial subsidiaries in Europe, United States, Mexico, Brazil, China, Australia and Israel. In other countries, the Group operates through an international network of over 200 independent distributors.

1H 2019

Managerial outlook on reported data.
Change 1H2019 vs. 1H2018 @ CER

FY 2017

Managerial outlook on reported data.
Change FY2017 vs. FY2016 @ CER

PRESENCE

[{"id":"nord-america","title":"NORTH AMERICA","content":"

188.1 €/MLN

28.1% OF SALES

+0.8%

"}, {"id":"usa","title":"USA","content":"

+0.7%

"}, {"id":"messico","title":"MEXICO","content":"

+9.6%

"}, {"id":"america-latina","title":"LATIN AMERICA","content":"

42.2 €/MLN

6.3% OF SALES

-2.2%

"}, {"id":"brasile","title":"BRAZIL","content":"

-6.2%

"}, {"id":"francia","title":"FRANCE","content":"

+12.0%

"}, {"id":"germania","title":"GERMANY","content":"

+16.5%

"}, {"id":"italia","title":"ITALY","content":"

+12.2%

"}, {"id":"australia","title":"AUSTRALIA","content":"

+17.4%

"}, {"id":"cina","title":"CHINA","content":"

+5.8%

"}, {"id":"asia-pacifico","title":"ASIA PACIFIC","content":"

129.4 €/MLN

19.3% OF SALES

+13.5%

"}, {"id":"europa-africa","title":"EUROPE & AFRICA","content":"

309.5 €/MLN

46.3% OF SALES

+11.7%

"} ]
[{"id":"nord-america","title":"NORTH AMERICA","content":"

101.2 €/MLN

28.9% OF SALES

+1.6%

"}, {"id":"usa","title":"USA","content":"

+3.3%

"}, {"id":"messico","title":"MEXICO","content":"

+11.0%

"}, {"id":"america-latina","title":"LATIN AMERICA","content":"

20.0 €/MLN

5.7% OF SALES

-5.2%

"}, {"id":"brasile","title":"BRAZIL","content":"

-8.2%

"}, {"id":"francia","title":"FRANCE","content":"

-3.3%

"}, {"id":"germania","title":"GERMANY","content":"

+0.7%

"}, {"id":"italia","title":"ITALY","content":"

+21.6%

"}, {"id":"australia","title":"AUSTRALIA","content":"

+10.7%

"}, {"id":"cina","title":"CHINA","content":"

+10.7%

"}, {"id":"asia-pacifico","title":"ASIA PACIFIC","content":"

64.7 €/MLN

18.5% OF SALES

+6.3%

"}, {"id":"europa-africa","title":"EUROPE & AFRICA","content":"

164.3 €/MLN

46.9% OF SALES

+5.1%

"} ]